Philip Koo: Hi, this is Phillip Koo, the Editor for the Center of Excellence on Imaging at UroToday.com. Today, we’re very fortunate to have with us the second lecture in the new SNMMI lecture series on prostate cancer imaging and therapies. We’re very fortunate to have with us today Dr. Savir-Baruch, who is the Assistant […]
Charles Ryan: Hello, I’m joined today by Dr. Pamela Munster. Dr. Munster is a researcher on breast cancer and the hereditary genetics of breast cancer, but also an entrepreneur in the area of prostate cancer. She’s developing a device, for the treatment of early-stage prostate cancer. Thank you for joining us, and let’s talk a […]
Petros Grivas: Hello. I’m Petros Grivas. I’m a medical oncologist at the Seattle Cancer Care Alliance and Associate Professor of Medicine in University of Boston and Fred Hutchinson Cancer Research Center. I’m thrilled today to host Dr. Neeraj Agarwal, who is a full Professor of Medicine at the Huntsman Cancer Institute, University of Utah and […]
Bladder cancer is one of the most common malignant tumors in humans. Over the last several years, a significant problem has been observed related to the diagnosis and treatment of bladder cancer. Research is underway on diagnostic and therapeutic methods that aim to reduce rates of recurrence and progression of bladder cancer. In current publications, […]
Non-muscle-invasive bladder cancer (NMIBC) causes a considerable health burden due to the high recurrence and progression rates. Past studies have identified multiple candidate loci associated with NMIBC prognosis, albeit lacking validation. Moreover, scarce reports exist on genetic susceptibility to independent prognostic predictors of NMIBC, such as stage or grade. To investigate genetic associations with NMIBC […]
Bladder cancer (BC) is one of the most common malignant tumors in the urinary system. The discovery of prognostic biomarkers is still one of the major challenges to improve clinical treatment of BC patients. In order to assist biologists and clinicians in easily evaluating the prognostic potency of genes in BC patients, we developed a […]
Bladder cancer is a “Warburg-like” tumor characterized by a reliance on aerobic glycolysis and expression of pyruvate kinase M2 (PKM2). PKM2 oscillates between an active tetramer and an inactive dimer. We aim to further characterize PKM2, in particular PKM2 dimer, as a urinary biomarker of bladder cancer and a potential target for treatment. HTB-9, HTB-5, […]
To assess the added value of concomitant systematic biopsies (SB) for final grade group prediction in MRI positive patients undergoing targeted biopsies (TB). We included 478 consecutive patients had a pre-biopsy positive mpMRI, a >10-core SB combined with fusion TB, and a RP. The primary endpoint was the grade group concordance between biopsy and RP […]
Two recent observational studies have investigated the association between androgen deprivation therapy (ADT) and rheumatoid arthritis (RA), but generated discrepant findings and had important methodological limitations. Thus, the objective of this study was to determine whether the use of ADT is associated with an increased risk of RA in men with prostate cancer. We conducted […]
Background The survival rate of prostate cancer is relatively higher than other cancers, therefore, the health-related quality of life (HRQoL) becomes a critical issue for the patients. There are limited quality of life data evaluating the difference between androgen deprivation therapy and non-androgen deprivation therapy. Objective To evaluate the HRQoL among prostate cancer patients with androgen deprivation […]
